Summit Therapeutics
Akeso Says Ivonescimab Beat Pembrolizumab on Survival
Akeso, Inc. (HKEX: 9926.HK) announced on September 2 that a pre-specified interim analysis of overall survival in its Phase III HARMONi-2 trial met the study’s key secondary endpoint, with what the company describes as a statistically significant and clinically meaningful improvement for ivonescimab over pembrolizumab. Notably, the release does not disclose the actual hazard ratio,…
